April 23, 2008 - Med BioGene Inc. (TSX Venture: MBI) and the University Health Network (UHN) announced that they have entered into license and collaboration agreements providing MBI with exclusive, world-wide rights to develop and commercialize a critical prognostic test for early stage non-small-cell lung cancer developed by UHN. The test will be marketed under MBI’s trade name LungExpress Dx™.LungExpress Dx™ is a gene expression-based assay that provides valuable information regarding each patient’s prognosis for survival to more effectively guide treatment and improve the selection of patients for chemotherapy following surgical removal of their cancerous tumour... Med BioGene's Press Release -
